TGen to lead the first patient in the clinical trial studies to test new drugs for glioblastoma -
glioblastoma pilot funded by the Ivy Foundation
in 2012, the Ben and Catherine Ivy Foundation awarded $ 10 million in grants to two research projects on the brain revolutionary cancer at the Translational Genomics research Institute (TGen). One project officially received final regulatory approval from the University of California, San Francisco, meaning that patient enrollment in the trial can begin.
In the proposed $ 5 million, "Genomics Enabled Medical glioblastoma trial," TGen and its clinical partners lead early in patients of clinical trial studies that will test promising new drugs that could extend the survival of GBM patients. This multi-part study will take place in clinics across the country and TGen laboratories.
"GBM is one of the top three most cancers kill fast-la- low and it affects people of all ages, "said Catherine (Bracken) Ivy, founder and president of the Ben and Catherine Ivy Foundation. "It is essential that we fund research that will help patients live longer so we can investigate and treat brain cancer."
The project began with a pilot study on 15 patients, using whole genome sequencing to study their tumor samples to help doctors determine which medications might be more beneficial.
to support clinical decisions molecularly, the TGen lab also examine genomic data from at least 536 past cases of glioblastoma, and new cases of tumor samples, development tools for produce more insight into how glioblastoma tumors grow and survive. TGen also conduct a series of pioneering laboratory tests to measure cell responses cell to various drugs.
"GBM is a disease that needs answers now, and we firmly believe these answers are found in the genome," said Dr. David Craig, TGen Deputy Director of Bioinformatics, Director of the Neurogenomics Division TGen, and one of the principal investigators projects. "Identifying the genes that contribute to the survival of glioblastoma will provide valuable information on how to treat it, and can also lead to a better understanding of what motivates other cancers."
for new treatments to patients as quickly as possible, this five-year study will include a feasibility study involving up to 30 patients, follow-up Phase II clinical trial with as many as 70 patients. TGen teamed with Ivy Early clinical trials Consortium phase which comprises: University of California, San Francisco; University of California, Los Angeles; the MD Anderson Cancer Center; Cancer Center Memorial Sloan Kettering; University of Utah; and the Dana-Farber / Harvard Cancer Center.
The results of these clinical trials should not only help patients who join them, but also to provide the data necessary for FDA approval and availability of new drugs that could benefit tens of thousands of brain cancer patients in the future.
"Working with doctors, the project will aim to include treatment as part of the molecular profile of the tumor. We have the opportunity to determine when combinations of drugs may be more effective than ' use a single drug, quickly identify therapies that do not work, and to accelerate the discovery of those who could prove promising for future development, "said Dr. John Carpten, deputy director of TGen basic sciences, director integrated genomics Division TGen cancer, and one of the principal investigators of the project.
in addition to helping patients as quickly as possible, the project is expected to significantly expand the network of Arizona expert brain cancer.
EmoticonEmoticon